awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38695896-5D2EB40C-CBEC-4466-86FA-3794445D9407
Q38695896-5D2EB40C-CBEC-4466-86FA-3794445D9407
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38695896-5D2EB40C-CBEC-4466-86FA-3794445D9407
Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.
P2860
Q38695896-5D2EB40C-CBEC-4466-86FA-3794445D9407
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38695896-5D2EB40C-CBEC-4466-86FA-3794445D9407
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0c83be89c115898dad74eb0fdc38715b3fe0a83d
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer